Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NVCT Nuvectis Pharma Inc
- Stocks
- Healthcare
- NASDAQ: NVCT
Price (delayed)
$7.31
Market cap
$172.77M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.13
Enterprise value
$142.9M
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock
Highlights
The equity has soared by 116% from the previous quarter and by 49% YoY
NVCT's EPS is up by 20% year-on-year
NVCT's quick ratio has soared by 56% since the previous quarter but it is down by 5% year-on-year
The net income has grown by 10% YoY but it has contracted by 6% from the previous quarter
Key stats
What are the main financial stats of NVCT
Market
Valuations
Earnings
Shares outstanding
23.63M
Market cap
$172.77M
Enterprise value
$142.9M
Price to earnings (P/E)
N/A
Price to book (P/B)
8.16
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$21.02M
Net income
-$20.16M
EBIT
-$20.16M
EBITDA
-$20.16M
Free cash flow
-$12.06M
Per share
Balance sheet
Liquidity
EPS
-$1.13
EPS diluted
-$1.13
Free cash flow per share
-$0.61
Book value per share
$0.9
Revenue per share
$0
TBVPS
$1.51
Total assets
$30.15M
Total liabilities
$9.19M
Debt
$0
Equity
$20.95M
Working capital
$20.95M
Debt to equity
0
Current ratio
3.28
Quick ratio
3.25
Net debt/EBITDA
1.48
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-95.6%
Return on equity
-148.8%
Return on invested capital
N/A
Return on capital employed
-96.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NVCT stock price
How has the Nuvectis Pharma stock price performed over time
Intraday
-2.14%
1 week
-8.4%
1 month
-22.32%
1 year
18.28%
YTD
35.12%
QTD
-2.14%
Financial performance
How have Nuvectis Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$21.02M
Net income
-$20.16M
Gross margin
N/A
Net margin
N/A
The net income has grown by 10% YoY but it has contracted by 6% from the previous quarter
The operating income rose by 9% year-on-year but it has declined by 6% since the previous quarter
Price vs fundamentals
How does NVCT's price correlate with its fundamentals
Growth
What is Nuvectis Pharma's growth rate over time
Valuation
What is Nuvectis Pharma stock price valuation
P/E
N/A
P/B
8.16
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NVCT's EPS is up by 20% year-on-year
The equity has soared by 116% from the previous quarter and by 49% YoY
NVCT's P/B is 20% lower than its last 4 quarters average of 10.4
Efficiency
How efficient is Nuvectis Pharma business performance
The ROA has increased by 8% YoY and by 7% QoQ
The ROE has grown by 7% from the previous quarter but it has contracted by 5% YoY
Dividends
What is NVCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NVCT.
Financial health
How did Nuvectis Pharma financials performed over time
Nuvectis Pharma's total assets has soared by 62% from the previous quarter and by 53% YoY
The total liabilities has surged by 62% year-on-year and by 3.4% since the previous quarter
NVCT's debt is 100% lower than its equity
The equity has soared by 116% from the previous quarter and by 49% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.